Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience
Open Access
- 1 January 2019
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 12
Abstract
Tofacitinib is an oral small molecule directed against the JAK/STAT pathway, blocking the inflammatory cascade. Oral formulation of tofacitinib has recently been approved for the treatment of patients with moderate–severe ulcerative colitis. Its efficacy and safety have been demonstrated in three phase III clinical trials and confirmed by promising real-life data. The purpose of this review is to summarize the available evidence on the efficacy and safety of tofacitinib and to define its role and position in the treatment algorithms for patients with ulcerative colitis.Keywords
This publication has 32 references indexed in Scilit:
- Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trialBritish Journal of Dermatology, 2014
- Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid ArthritisArthritis & Rheumatology, 2014
- Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension StudiesThe Journal of Rheumatology, 2014
- The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Tofacitinib, a Janus Kinase Inhibitor, in HumansDrug Metabolism and Disposition, 2014
- Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel diseasePharmacological Research, 2013
- Overview of safety of non-biologic and biologic DMARDsRheumatology, 2012
- Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative ColitisNew England Journal of Medicine, 2012
- Increased IL-17A expression in granulomas and in circulating memory T cells in sarcoidosisRheumatology, 2011
- Epidemiology and Natural History of Inflammatory Bowel DiseasesGastroenterology, 2011
- Janus kinases in immune cell signalingImmunological Reviews, 2009